An observational study in Short Bowel Syndrome, Hyperoxaluria and Hyperoxalemia, sponsored by Hospices Civils de Lyon. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-07-21.
Sponsored by Hospices Civils de Lyon · Observational
Hyperoxaluria due to fat malabsorption is seen in patients suffering from short bowel and can lead to stones and nephrocalcinosis. Not all patients are prone to these renal complications. only urinary oxaluria is measured in practice. Plasma oxalate shouldn't increase theoretically in these patients. However recent report showed an increase of plasma oxalate in patient with enteric hyperoxaluria. The aim of this study is to assess the plasma oxalate distribution in this specific population to have a new tool to predict renal complication of these patients.
149 studies on the registry are indexed under Short Bowel Syndrome; 25 are open to participants now.
This study's enrollment of 47 is below the median of 53 across 36 observational studies indexed under Short Bowel Syndrome.
Browse Short Bowel Syndrome studies →Hospices Civils de Lyon is the lead sponsor of 1,826 studies on the registry; 439 are open to participants now.
Counted across the registry records on this site, refreshed daily.
type II short bowel patient
Exclusion Criteria:
blood sampling will be used to perform oxalemia and FGF23 quantitative analysis
urine sampling will be used to measure glycolate urinary rate (glycolaturia) and to perform urinary inflammation markers quantitative analysis
PWV will be measured thank to the Complior® device
central pressure will be measured thank to the Complior® device
Plasma oxalate rate (oxalemia)
this sample measures the plasma oxalate rate
Time frame: at inclusion
This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospices Civils de Lyon